Goldman Sachs Downgrades Covidien Ltd (COV) to Neutral On End-Market Weakness
Tweet
Share
E-mailGet Alerts COV Hot Sheet
Price: $106.71 --0%
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs downgraded Covidien Ltd (NYSE: COV) from Buy to Neutral with a price target of $49 saying end-market weakness likely drives downside to Street estimate.
The firm is cutting estimates and its price target reflect sustained weak utilization (US/EU), greater price pressure in developed markets, and FX.
For an analyst ratings summary and ratings history on Covidien Ltd click here. For more ratings news on Covidien Ltd click here.
Shares of Covidien Ltd closed at $46.17 yesterday.
The firm is cutting estimates and its price target reflect sustained weak utilization (US/EU), greater price pressure in developed markets, and FX.
For an analyst ratings summary and ratings history on Covidien Ltd click here. For more ratings news on Covidien Ltd click here.
Shares of Covidien Ltd closed at $46.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Wedbush Downgrades Globant S.A. (GLOB) to Neutral on balanced risk/reward
- JPMorgan Downgrades HomeCo Daily Needs REIT (HDN:AU) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
